Table 4.
Study 2: results from strength testing (mean ±95% CI). Superscripts indicate significance—groups that do not share the same letter are significantly different (1-way ANOVA with Tukey post-hoc analysis). DC2: decellularisation process with acetone permanently included, TPAA: terminal peracetic acid treatment, PAAbio: peracetic acid bioburden treatment, ABbio: antibiotic bioburden treatment.
| Group | σT (MPa) | εT (mm mm−1) | A (MPa) | B (dim’less) | AB (MPa) | UTS (MPa) | E (MPa) | εFAIL (mm mm−1) |
|---|---|---|---|---|---|---|---|---|
| Native | 9.83±1.68(a) | 0.086±0.001(a) | 0.40±0.12(a) | 50.63±3.19(a) | 19.97±5.27(a) | 52.22±4.62(a, b) | 235.15±31.56(a) | 0.315±0.028(a) |
| DC2+TPAA | 14.22±4.07(a, b) | 0.096±0.005(a) | 1.11±0.29(a) | 37.77±5.54(a, b) | 40.72±5.68(a) | 46.41±7.60(b) | 211.29±24.89(a) | 0.297±0.023(a) |
| DC2−TPAA | 15.72±4.12(a, b) | 0.107±0.016(a, b) | 1.28±0.57(a) | 36.06±8.24(a, b) | 41.80±12.49(a) | 45.67±1.06(b) | 232.89±15.33(a) | 0.276±0.013(a) |
| DC2+PAAbio+TPAA | 16.94±3.40(a, b) | 0.148±0.031(b, c) | 0.94±0.39(a) | 30.68±10.33(b) | 23.67±4.98(a) | 51.12±8.12(a, b) | 240.92±38.18(a) | 0.312±0.030(a) |
| DC2+PAAbio−TPAA | 18.21±1.48(b) | 0.153±0.024(c) | 0.91±0.66(a) | 29.12±3.05(b) | 25.26±16.70(a) | 49.94±5.10(a, b) | 266.27±43.65(a) | 0.313±0.023(a) |
| DC2+ABbio+TPAA | 18.19±3.58(b) | 0.120±0.021(a, b, c) | 1.24±0.53(a) | 33.53±5.86(b) | 38.26±11.26(a) | 65.18±9.70(a) | 317.13±43.78(a) | 0.292±0.028(a) |
| DC2+ABbio−TPAA | 18.53±3.29(b) | 0.116±0.021(a, b, c) | 1.26±0.53(a) | 34.77±5.78(b) | 40.14±10.97(a) | 61.52±4.53(a, b) | 296.77±25.59(a) | 0.267±0.018(a) |